Ned Mozier

Ned received a Ph.D. in biochemistry at the University of Louisville and was employed in the pharmaceutical industry for 35 years, retiring in 2024. At Pfizer he held a number of scientific roles, including leadership of Pfizer’s bioassay and impurity group for 10 years. His last job at Pfizer was as Vice President for CMC development for Pfizer’s large molecule and vaccine early clinical portfolio. Ned has contributed to the development and commercialization of many biological products and vaccines. Throughout his career he has published and led conferences championing the use of in vitro alternatives to animal testing. He continues to speak at scientific conferences and lead USP committees and panels.